Dicot Pharma Dicot Pharma
På svenska

Dicot Pharma in a favourable financial position following TO 6

With a subscription rate of 96%, generating SEK 43.8 million, the exercise of warrants enables us to continue pursuing our ambitious development plan.

Strong development since the listing on Nasdaq First North

Phase 2a results to be reported this autumn

On our journey towards offering the market the next generation erectile dysfunction treatments, our development work is currently in clinical phase 2.

  • Home/
  • Investor Relations

Investor Relations

Dicot Pharma aims to launch the drug candidate LIB-01 globally and become the first-choice treatment for erectile dysfunction and premature ejaculation. Our global ambition means we are gradually increasing international efforts in development, business, and communications.

Dicot Pharma currently has over 15,300 shareholders. Since 2024, the stock has been listed on Nasdaq First North Stockholm.

IR Contact

Elin Trampe

CEO

Email: [email protected]
Telephone: +46 72 502 1010